Lung Cancer Clinical Trial

Gain-framed Messages and NRT for Lung Cancer Screening Patients

Summary

This research is a randomized smoking cessation trial conducted within and specifically personalized for lung cancer screening patients presenting to a lung screening clinic. Novel tobacco treatments for this population are critically needed, given the growing population of lung screening patients, which will grow dramatically now that lung screening is an approved CMS benefit. In the proposed study, we will test a gain-framed messaging intervention specifically designed for lung screening patients (vs. unframed messaging), as well as evaluating NRT sampling (vs. no medication) at 2 study sites. Our project is designed to be translational (in that it can be transferable from our controlled efficacy study to other lung screening programs).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

50 years or older
at least a 20-pack year history of smoking
current smoker (defined as any smoking in the past 30 days)
willing to be randomized
English speaking

Exclusion Criteria:

unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, severe alcohol dependence, or dementia,
known allergy to adhesives
being in the immediate (within 2 weeks) post myocardial infarction period
serious arrhythmias
unstable angina pectoris
hemodynamically or electrically unstable.
current participation in another tobacco treatment program (e.g., using medication from a primary care doctor, Quitline, etc.)

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

367

Study ID:

NCT03069924

Recruitment Status:

Recruiting

Sponsor:

Medical University of South Carolina

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Yale Cancer Center
New Haven Connecticut, 06510, United States More Info
Alison Serrantino
Contact
203-464-7850
[email protected]
Lisa Fucito, PhD
Principal Investigator
Medical University of South Carolina
Charleston South Carolina, 29425, United States More Info
Marian Chelsea Evangelista
Contact
843-509-7589
[email protected]
Benjamin Toll, PhD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

367

Study ID:

NCT03069924

Recruitment Status:

Recruiting

Sponsor:


Medical University of South Carolina

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.